Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Hepatitis C

Free Subscription Articles published in J Viral Hepat Retrieve available abstracts of 138 articles: HTML format

Single Articles

February 2026
1. KARICHASHVILI L, Shadaker S, Schumacher IT, Tsereteli M, et al
   Assessing the Seroprevalence of and Knowledge, Attitudes and Practices Related to Hepatitis B and Hepatitis C Among Dental Health Professionals in the Country of Georgia, 2023.
   J Viral Hepat. 2026;33:e70126.
   PubMed     Abstract available
   
   
   
2. GERBAUD C, Debette-Gratien M, Guillouche P, Francois C, et al
   Managing Hepatitis C in Addiction Care Centers: Results of the French Real-Life NeoVie Study.
   J Viral Hepat. 2026;33:e70121.
   PubMed     Abstract available
   
   
   
3. YIN S, Hofmeister MG, Thompson ND, Teshale EH, et al
   Characteristics of Newly Reported Chronic Hepatitis C Cases Among Adults in the United States, 2016-2023: Insights From Population-Based Surveillance.
   J Viral Hepat. 2026;33:e70123.
   PubMed     Abstract available
   
   
   January 2026
4. FAN S, Imsirovic H, Garber G, Kelly E, et al
   Time to Hepatitis C Care Engagement and Treatment Outcomes in Canadian Immigrants Have Markedly Improved Over Three Decades.
   J Viral Hepat. 2026;33:e70112.
   PubMed     Abstract available
   
   
   
5. BIONDI MJ, Capraru CI, Harper B, Gill P, et al
   Pharmacist-Led Hepatitis C Diagnosis and Rapid Management-In Community (PHARM-C): Results From a Phase IV Nonblinded Randomised Controlled Trial.
   J Viral Hepat. 2026;33:e70109.
   PubMed     Abstract available
   
   
   
6. MAZZILLI S, Aslam MK, Ahmed M, Wailly Y, et al
   Decentralised Hepatitis C Management: A Simplified, Integrated Model of Care in a Primary Health Centre in Pakistan, August 2022-June 2023.
   J Viral Hepat. 2026;33:e70103.
   PubMed     Abstract available
   
   
   
7. FEELEMYER J, Ban FK, Braithwaite RS, Bhattacharya D, et al
   Associations Between Prior and Current Unhealthy Alcohol Use and Liver Morbidity Risk and Mortality Among Veterans With a History of Hepatitis C Who Have Achieved Sustained Virological Response.
   J Viral Hepat. 2026;33:e70116.
   PubMed     Abstract available
   
   
   
8. 
   Correction to 'A Contactless Cure: Leveraging Telehealth to Improve Hepatitis C Treatment at a Safety-Net Hospital'.
   J Viral Hepat. 2026;33:e70117.
   PubMed    
   
   
   December 2025
9. MARCELLIN F, di Beo V, Sogni P, Ramier C, et al
   Bridging the Gap: How Distance to Hospitals Limits HCV Treatment Initiation in France.
   J Viral Hepat. 2025;32:e70102.
   PubMed    
   
   
   November 2025
10. GONZALEZ CJ, Perez-Mejia CN, Hernandez N, Kapadia SN, et al
    Identifying Varying Influences on Eliminating Hepatitis C Across Medical Specialties.
    J Viral Hepat. 2025;32:e70093.
    PubMed     Abstract available
    
    
    
11. LAUREILLARD D, Binh NT, Vinh VH, Hong TT, et al
    High Efficiency and Safety of Hepatitis C Treatment Among People Who Inject Drugs in Vietnam.
    J Viral Hepat. 2025;32:e70090.
    PubMed     Abstract available
    
    
    
12. GHANY MG, Ward JW, Baldwin Z, Jiao S, et al
    HCV Testing and Treatment of Adults in the United States: 2014 Through 2021-Data From Two National Commercial Testing Laboratories.
    J Viral Hepat. 2025;32:e70087.
    PubMed     Abstract available
    
    
    
13. QURESHI H, Canchola JA, Hai G, Latif AQ, et al
    Evaluation of Blood Droplet Volumes on the Cobas Plasma Separation Card for HCV RNA Testing in Resource-Limited Settings.
    J Viral Hepat. 2025;32:e70091.
    PubMed     Abstract available
    
    
    
14. OLTMANNS C, Witte M, Wranke A, Deterding K, et al
    HBV Dominance Is Associated With a Distinct Inflammatory Milieu in HBV/HCV Coinfection.
    J Viral Hepat. 2025;32:e70092.
    PubMed     Abstract available
    
    
    
15. GRANTZ KH, Cummings DAT, Romero LM, Astemborski J, et al
    Impact of Risk Heterogeneity on the Feasibility of Hepatitis C Elimination Among People Who Inject Drugs: A Modelling Study.
    J Viral Hepat. 2025;32:e70096.
    PubMed     Abstract available
    
    
    
16. HARDIE DR, Korsman SNJ, Valley-Omar Z, Petersen N, et al
    Performance Evaluation of the Elecsys HCV Duo Immunoassay in the Public Healthcare Setting in Cape Town, South Africa.
    J Viral Hepat. 2025;32:e70095.
    PubMed     Abstract available
    
    
    October 2025
17. HANDANAGIC S, Shadaker S, BaliashvilI D, Schumacher IT, et al
    Demographic and Clinical Characteristics of Patients With Hepatitis C and Hepatitis B Co-Infection, Georgia, 2017-2023.
    J Viral Hepat. 2025;32:e70067.
    PubMed     Abstract available
    
    
    
18. TORGERSEN J, Smookler D, Russell R, Gasior J, et al
    Early Read-Time Performance of the OraQuick HCV Rapid Antibody Assay for the Exclusion of HCV Viremia.
    J Viral Hepat. 2025;32:e70066.
    PubMed     Abstract available
    
    
    
19. KASSA GM, Lim AG, Tamiru MT, Alamneh TS, et al
    Risk Factors for Hepatitis C Virus Among the General Population in Sub-Saharan Africa-An Analysis of Systematic Review Data.
    J Viral Hepat. 2025;32:e70065.
    PubMed     Abstract available
    
    
    
20. CONWAY A, Grebely J, Treloar C, Matthews S, et al
    Policymaker Perspectives on the Role of Health Systems in Sustainable Hepatitis C Point-Of-Care Testing in Australia.
    J Viral Hepat. 2025;32:e70080.
    PubMed     Abstract available
    
    
    
21. XIAO J, Zhang X, Mao X, Lai S, et al
    Efficacy and Safety of Velpatasvir Plus Sofosbuvir With or Without Ribavirin in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2025;32:e70078.
    PubMed     Abstract available
    
    
    
22. LUONG CL, Ellett LK, Pratt N, Staff K, et al
    Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024.
    J Viral Hepat. 2025;32:e70082.
    PubMed     Abstract available
    
    
    
23. VOJT G, Bonnet P, Scott J, Hathorn E, et al
    Peer-Delivered Outreach With Rapid Treatment Pathways for Hepatitis C Testing and Treatment Among Unhoused People.
    J Viral Hepat. 2025;32:e70085.
    PubMed     Abstract available
    
    
    September 2025
24. WANG M, Wang Y, Yang Z, Yang C, et al
    Clinical Observational Study on HBV Reactivation After Direct-Acting Antiviral Therapy in HCV/HBV Coinfected Patients in Guizhou, China.
    J Viral Hepat. 2025;32:e70061.
    PubMed     Abstract available
    
    
    
25. BOUDOVA S, Iyer NS, Tholey DM, Fenkel JM, et al
    The Effect of HCV on Methadone Dose During Pregnancy.
    J Viral Hepat. 2025;32:e70060.
    PubMed     Abstract available
    
    
    
26. GREEN F, Simmons R, Leeman D, Desai M, et al
    Global Systematic Review of the Measurement of Stigma Associated With People Living With Hepatitis B or Hepatitis C Viruses.
    J Viral Hepat. 2025;32:e70064.
    PubMed     Abstract available
    
    
    
27. REMY AJ, Bellon S, Smadhi R, Bottlaender J, et al
    HCV Screening Before Endoscopy in Hepatogastroenterology Outpatient Clinic: The Depist C Endo Study.
    J Viral Hepat. 2025;32:e70063.
    PubMed     Abstract available
    
    
    August 2025
28. LI Y, Li Z, Chen R, Jia C, et al
    Global, Regional and National Burden of Chronic Hepatitis C, 1990-2021: A Systematic Analysis for the GBD Study 2021.
    J Viral Hepat. 2025;32:e70053.
    PubMed     Abstract available
    
    
    
29. HEATH K, Guzman R, Elsum I, Wade AJ, et al
    Balancing Efficiency and Accuracy in Hepatitis C Rapid Antibody Testing: Insights From a Cluster Randomised Crossover Trial.
    J Viral Hepat. 2025;32:e70043.
    PubMed     Abstract available
    
    
    
30. SONGTANIN B, Flores J, Barba R, Saba J, et al
    Occult Hepatitis C Virus Infection: A Narrative Review.
    J Viral Hepat. 2025;32:e70051.
    PubMed     Abstract available
    
    
    
31. CONWAY B, Yi S, Truong D
    CHIME: Sofosbuvir/Velpatasvir (S/V) for the Treatment of HCV Infection Among Vulnerable Inner-City Residents.
    J Viral Hepat. 2025;32:e70057.
    PubMed     Abstract available
    
    
    July 2025
32. ELBAZ T, Al-Naamani K, Abosheaishaa H, Alswat K, et al
    Leading Role of Sofosbuvir/Daclatasvir in Achieving Hepatitis C Elimination in Egypt.
    J Viral Hepat. 2025;32:e70032.
    PubMed     Abstract available
    
    
    
33. SHIHA G, Helmy A, Mikhail N, Hassan A, et al
    Long Term Clinical Outcomes in Chronic Hepatitis C Patients Who Achieved SVR Following DAAs: A Decade Long Prospective Study.
    J Viral Hepat. 2025;32:e70044.
    PubMed     Abstract available
    
    
    
34. ADEBAJO A, Qiao S, Esu I, Olatosi B, et al
    The Efficacy and Sustainability of an Implementation Intervention (FOCUS Program) on Linkage to Hepatitis C Care Time at a Community Health Center in the Deep South: A Longitudinal Study Based on Electronic Medical Records.
    J Viral Hepat. 2025;32:e70045.
    PubMed     Abstract available
    
    
    
35. RAYNER D, McCullough F, McQue K, Jones K, et al
    Prospective Evaluation of Blood Borne Virus Testing in Custody Suites in North-East England.
    J Viral Hepat. 2025;32:e70042.
    PubMed     Abstract available
    
    
    
36. TAKAKI S, Ohya K, Mori N, Ochi H, et al
    Hepatitis C Patients Over the Age of 75 Should Be Treated With Direct-Acting Antivirals, as Their Prognosis With Treatment Is Similar to That of Uninfected Healthy Individuals of the Same Age.
    J Viral Hepat. 2025;32:e70048.
    PubMed     Abstract available
    
    
    June 2025
37. LI S, Dong W, Yu Y, Yang Z, et al
    A Government-Led, Patient-Centric Strategy to Re-Engage Diagnosed but Untreated Hepatitis C Patients in Yunnan Province, China.
    J Viral Hepat. 2025;32:e70028.
    PubMed     Abstract available
    
    
    
38. SI NAFA SA, Benali S, Penaranda G, Deuffic-Burban S, et al
    Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study.
    J Viral Hepat. 2025;32:e70038.
    PubMed     Abstract available
    
    
    May 2025
39. WANG X, Yan X, He B, Li B, et al
    Global Burden and Trends of Acute Hepatitis C From 1990 to 2021: An Analysis Based on the 2021 Global Burden of Disease Study.
    J Viral Hepat. 2025;32:e70026.
    PubMed     Abstract available
    
    
    April 2025
40. VAITTINADA AYAR P, Abdelkader J, Gay M, Allali R, et al
    Systematic Screening for Hepatitis B, C, and HIV and Linkage to Care in Patients With Mental Health Disorders Admitted to the Emergency Department.
    J Viral Hepat. 2025;32:e70018.
    PubMed     Abstract available
    
    
    
41. AHMED S, Nadir MA, Farooqi HA, Ashraf H, et al
    Enhancing Hepatitis C Management: Mortality Trends and Disparities in the US by Sex, Age Group, Race/Ethnicity and Region (1999-2020).
    J Viral Hepat. 2025;32:e70011.
    PubMed     Abstract available
    
    
    
42. SUN J, Kelly M, Tsheten T, Pourmarzi D, et al
    Prevalence of Hepatitis C Among Migrants: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2025;32:e70025.
    PubMed     Abstract available
    
    
    
43. POWELL AA, Costella A, Roche R, Leeman D, et al
    Sensitivity Analysis of Hepatitis B and C Mortality in England Using Data Linkage: Meeting the WHO Elimination Threshold for Mortality.
    J Viral Hepat. 2025;32:e70016.
    PubMed     Abstract available
    
    
    March 2025
44. BARRE T, Ramier C, Ory K, Saidi T, et al
    Liver Enzyme Elevation After Hepatitis C Virus Cure: Is There a Sex Effect? (ANRS CO13 HEPAVIH Cohort).
    J Viral Hepat. 2025;32:e70007.
    PubMed    
    
    
    
45. CHELOUAH S, Nna H, Angijiro P, Thomas F, et al
    Screening, Prevalence and Management of Chronic Viral Hepatitis C in Mental Health Setting: Towards the Eradication of A Forgotten Reservoir.
    J Viral Hepat. 2025;32:e70014.
    PubMed     Abstract available
    
    
    February 2025
46. EMERY H, Evans C, Jack K, Martello E, et al
    A Qualitative Systematic Review of Barriers and Facilitators to Hepatitis B and C Programmes in Prisons.
    J Viral Hepat. 2025;32:e14049.
    PubMed     Abstract available
    
    
    
47. PERERA H, Imsirovic H, Macphail G, Webster D, et al
    Resistance-Associated Substitution Testing Trends and Impact on HCV Treatment Outcomes in Canada: A CanHepC-CANUHC Analysis.
    J Viral Hepat. 2025;32:e14058.
    PubMed     Abstract available
    
    
    
48. SINGAL AG, Reddy KR, Colombo M, Morris HL, et al
    DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.
    J Viral Hepat. 2025;32:e14056.
    PubMed     Abstract available
    
    
    
49. HILTON B, De Angelis D, Mitchell H, Harris R, et al
    Heterogeneity in Risk and Implications for Hepatitis C Reinfection in People Who Inject Drugs in England.
    J Viral Hepat. 2025;32:e14052.
    PubMed     Abstract available
    
    
    
50. VOELLER AS, Johannessen A, Abebe ZZ, Adugna W, et al
    The Disease and Economic Burden of HBV and HCV in Ethiopia.
    J Viral Hepat. 2025;32:e14053.
    PubMed     Abstract available
    
    
    
51. ONG E, Xia T, Laing R, Richmond JA, et al
    Australian Community Pharmacists' Preparedness to Offer and Discuss Hepatitis C Testing and Treatment With Pharmacy Clients: A Representative Cross-Sectional Survey.
    J Viral Hepat. 2025;32:e70001.
    PubMed     Abstract available
    
    
    
52. MENNINI FS, Sciattella P, Simonelli C, Marcellusi A, et al
    Long-Term Effects of Direct-Acting Antivirals on Hepatitis C: Trends in Liver Disease-Related Hospitalisations in Italy.
    J Viral Hepat. 2025;32:e14061.
    PubMed     Abstract available
    
    
    
53. ELGRETLI W, Shengir M, Sasson S, Ramanakumar AV, et al
    Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors.
    J Viral Hepat. 2025;32:e70004.
    PubMed     Abstract available
    
    
    January 2025
54. QURESHI M
    A Health Systems Strengthening Approach to Address the High Burden of Hepatitis C in Pakistan.
    J Viral Hepat. 2025;32:e14050.
    PubMed     Abstract available
    
    
    
55. TSAI YN, Lo JC, Tseng CH, Hsieh SC, et al
    Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy.
    J Viral Hepat. 2025;32:1-8.
    PubMed     Abstract available
    
    
    
56. POOROLAJAL J, Shadi Y, Heshmati B
    Interaction Between Hepatitis B, Hepatitis C and Alcohol in the Development of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2025;32:e14042.
    PubMed     Abstract available
    
    
    November 2024
57. ROSECRANS A, Harris R, Clair AS, Rice M, et al
    Challenges and Opportunities for Treating Hepatitis C Amongst People Who Use Drugs: Experience of an Integrated Mobile Clinic in Baltimore City.
    J Viral Hepat. 2024 Nov 26. doi: 10.1111/jvh.14038.
    PubMed     Abstract available
    
    
    
58. YEW KC, Sim ASY, Hawkins R, Acharyya S, et al
    Real-World Evaluation of Point-of-Care Testing for Hepatitis C Antibodies: Navigating Hepatitis C Elimination Effort.
    J Viral Hepat. 2024 Nov 22. doi: 10.1111/jvh.14039.
    PubMed     Abstract available
    
    
    
59. KASSA GM, Weldemariam AG, Abrahim SA, French CE, et al
    Seroprevalence of Hepatitis C in Ethiopia: First National Study Based on the 2016 Ethiopian Demographic and Health Survey.
    J Viral Hepat. 2024 Nov 21. doi: 10.1111/jvh.14037.
    PubMed     Abstract available
    
    
    
60. FURL R, Scarsi KK, Sayles H, Anderson M, et al
    Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income Countries.
    J Viral Hepat. 2024 Nov 15. doi: 10.1111/jvh.14031.
    PubMed     Abstract available
    
    
    
61. DIRKS M, Hennemann AK, Grosse GM, Beer A, et al
    Long-Term Follow-Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon-Free and Interferon-Based Hepatitis C Virus Treatment.
    J Viral Hepat. 2024 Nov 6. doi: 10.1111/jvh.14033.
    PubMed     Abstract available
    
    
    October 2024
62. ETOORI D, Cococcia S, Srivastava A, Flanagan S, et al
    The Camden and Islington Viral Hepatitis Identification Tool (CIVHIT): Use of a Clinical Database Case-Finding Tool for Hepatitis B, Hepatitis C and HIV in Primary Care.
    J Viral Hepat. 2024 Oct 24. doi: 10.1111/jvh.14027.
    PubMed     Abstract available
    
    
    
63. GINNANE JF, Scott N, Radley A, Dillon JF, et al
    Cost-Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in Australia.
    J Viral Hepat. 2024 Oct 23. doi: 10.1111/jvh.14015.
    PubMed     Abstract available
    
    
    
64. MARTIN MT, Hietpas AR, Novak JL, Deming P, et al
    A National Survey of Pharmacist Involvement in Hepatitis C Virus Management in the United States.
    J Viral Hepat. 2024 Oct 22. doi: 10.1111/jvh.14014.
    PubMed     Abstract available
    
    
    
65. YI S, Wiesmann C, Truong D, Sharma S, et al
    Community Pop-Up Clinic: Cascade of Care and HCV Treatment of Vancouver's Inner-City PWID Populations.
    J Viral Hepat. 2024 Oct 19. doi: 10.1111/jvh.14023.
    PubMed     Abstract available
    
    
    
66. IWADARE T, Kimura T, Sugiura A, Okumura T, et al
    Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy.
    J Viral Hepat. 2024 Oct 15. doi: 10.1111/jvh.14025.
    PubMed     Abstract available
    
    
    
67. BALIASHVILI D, Merabishvili T, Tskhomelidze I, Tsereteli M, et al
    Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia.
    J Viral Hepat. 2024 Oct 14. doi: 10.1111/jvh.14022.
    PubMed     Abstract available
    
    
    
68. CHEN Y, Zhang X, Yan X, Wang L, et al
    A Programme of Hepatitis C Surveillance With Active Linkage to Care (HEAL) for Inpatients in Two Tertiary Hospitals in Jiangsu, China.
    J Viral Hepat. 2024 Oct 9. doi: 10.1111/jvh.14020.
    PubMed     Abstract available
    
    
    
69. PHAW NA, Rayner D, Johnson A, Thompson C, et al
    Harm Minimisation and Other Preventative Measures Must Improve to Reduce Transmission of Hepatitis C in Prisons.
    J Viral Hepat. 2024 Oct 7. doi: 10.1111/jvh.14017.
    PubMed    
    
    
    
70. ZHANG HL, Nemeth H, Woodhouse EW, Davenport CA, et al
    Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure.
    J Viral Hepat. 2024 Oct 3. doi: 10.1111/jvh.14009.
    PubMed     Abstract available
    
    
    
71. PATEL P, Wells MT, Wethington E, Shapiro M, et al
    United States Provider Experiences With Telemedicine for Hepatitis C Treatment: A Nationwide Survey.
    J Viral Hepat. 2024 Oct 1. doi: 10.1111/jvh.14010.
    PubMed     Abstract available
    
    
    
72. MAKUZA JD, Wong S, Morrow RL, Binka M, et al
    Impact of COVID-19 pandemic on hepatocellular carcinoma surveillance in British Columbia, Canada: An interrupted time series study.
    J Viral Hepat. 2024;31:592-600.
    PubMed     Abstract available
    
    
    September 2024
73. BARRE T, Parlati L, Bourliere M, Ramier C, et al
    Socioeconomic Deprivation Weighs Heavily on Liver Fibrosis and Mortality After Hepatitis C Cure (ANRS CO22 Hepather).
    J Viral Hepat. 2024 Sep 10. doi: 10.1111/jvh.14006.
    PubMed     Abstract available
    
    
    
74. GRANTZ KH, Cepeda J, Astemborski J, Kirk GD, et al
    Individual Heterogeneity and Trends in Hepatitis C Infection Risk Among People Who Inject Drugs: A Longitudinal Analysis.
    J Viral Hepat. 2024 Sep 5. doi: 10.1111/jvh.13999.
    PubMed     Abstract available
    
    
    August 2024
75. THORNTON KA, Deming PD, Archer GRD, Ceniceros JA, et al
    Expanding Hepatitis C Virus Treatment in the New Mexico State Prison System: Using the ECHO Model for Provider and Prison Peer Education.
    J Viral Hepat. 2024 Aug 13. doi: 10.1111/jvh.13997.
    PubMed     Abstract available
    
    
    
76. IMSIROVIC H, Macphail G, Conway B, Fraser C, et al
    Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis.
    J Viral Hepat. 2024 Aug 12. doi: 10.1111/jvh.13995.
    PubMed     Abstract available
    
    
    
77. RUPASINGHE D, Choi JY, Kumarasamy N, Pujari S, et al
    Post-Diagnosis HCV RNA Testing Rates Prior to HCV Treatment Among People Living With HIV With HCV Antibody Positivity in the Asia-Pacific Region.
    J Viral Hepat. 2024 Aug 8. doi: 10.1111/jvh.13993.
    PubMed     Abstract available
    
    
    
78. FLISIAK R, Zarebska-Michaluk D, Janczewska E, Parfieniuk-Kowerda A, et al
    Sustained Virological Response After Early Discontinuation of Hepatitis C Treatment.
    J Viral Hepat. 2024 Aug 7. doi: 10.1111/jvh.13991.
    PubMed     Abstract available
    
    
    July 2024
79. TRAMONTI FANTOZZI MP, Ceccarelli L, Petri D, De Vita E, et al
    Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID-19 pandemic.
    J Viral Hepat. 2024 Jul 27. doi: 10.1111/jvh.13983.
    PubMed     Abstract available
    
    
    
80. ALAMNEH TS, Walker JG, Lim AG, Alam E, et al
    Changes in the prevalence of hepatitis B and C viral infections in Sindh province, Pakistan: Findings from two sero-surveys in 2007 and 2019.
    J Viral Hepat. 2024 Jul 26. doi: 10.1111/jvh.13986.
    PubMed     Abstract available
    
    
    
81. CHEN B, Iqbal U, Desai SK, Gries J, et al
    The role of treatment of hepatitis C with direct-acting antiviral agents on glycaemic control in diabetic patients: An updated systematic review and meta-analysis.
    J Viral Hepat. 2024 Jul 24. doi: 10.1111/jvh.13984.
    PubMed     Abstract available
    
    
    
82. BEYDOUN HA, Tsai J
    Screening rates for hepatitis B and C among low-income US veterans: Data from the National Veteran Homeless and Other Poverty Experiences Study.
    J Viral Hepat. 2024 Jul 10. doi: 10.1111/jvh.13981.
    PubMed     Abstract available
    
    
    June 2024
83. CLIPMAN SJ, Mehta SH, Mohapatra S, Srikrishnan AK, et al
    Network-based strategies to combat HCV: Examining social and spatial drivers of transmission among PWID in New Delhi.
    J Viral Hepat. 2024 Jun 4. doi: 10.1111/jvh.13960.
    PubMed     Abstract available
    
    
    
84. MOUSAVI S, Alavi M, Delavari A, Poustchi H, et al
    Towards hepatitis C virus elimination in Iran: A blueprint for comprehensive strategies.
    J Viral Hepat. 2024 Jun 3. doi: 10.1111/jvh.13975.
    PubMed     Abstract available
    
    
    May 2024
85. QURESHI H, Mahmood H, Nasir Z, Siddique S, et al
    A novel test and treat program for hepatitis C virus infection utilizing HCV core antigen testing, among police and general population, Islamabad, Pakistan, 2022.
    J Viral Hepat. 2024 May 21. doi: 10.1111/jvh.13953.
    PubMed     Abstract available
    
    
    
86. IRVIN R, Landry G, Jones MR, James A, et al
    High prevalence of hepatitis C virus infection among incarcerated persons: Results from the Louisiana Hepatitis C Elimination Plan's opt-out testing program in prisons.
    J Viral Hepat. 2024 May 17. doi: 10.1111/jvh.13941.
    PubMed     Abstract available
    
    
    
87. MESZAROS M, Coursier S, Nagot N, Moulis L, et al
    Screening for hepatitis C virus at the time of mammography using rapid diagnostic tests in women aged between 50 and 74 years (Mamm'OC NCT05067374).
    J Viral Hepat. 2024 May 15. doi: 10.1111/jvh.13947.
    PubMed     Abstract available
    
    
    
88. ROUSSOS S, Bagos C, Angelopoulos T, Chaikalis S, et al
    Incidence of primary hepatitis C infection among people who inject drugs during 2012-2020 in Athens, Greece.
    J Viral Hepat. 2024 May 14. doi: 10.1111/jvh.13951.
    PubMed     Abstract available
    
    
    April 2024
89. ALI M, Tucker JD, Kpokiri EE, Wu D, et al
    Crowdsourcing to increase hepatitis B and C testing and reduce hepatitis stigma among medical students in Bangladesh.
    J Viral Hepat. 2024 Apr 28. doi: 10.1111/jvh.13945.
    PubMed     Abstract available
    
    
    
90. HOLT B, Mendoza J, Nguyen H, Doan D, et al
    Barriers and enablers to people-centred viral hepatitis care in Vietnam and the Philippines: Results of a patient journey mapping study.
    J Viral Hepat. 2024 Apr 23. doi: 10.1111/jvh.13944.
    PubMed     Abstract available
    
    
    
91. ALQAHTANI SA, Yilmaz Y, El-Kassas M, Alswat K, et al
    Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt.
    J Viral Hepat. 2024 Apr 15. doi: 10.1111/jvh.13935.
    PubMed     Abstract available
    
    
    
92. OLTMANNS C, Bremer B, Kusche L, Stal P, et al
    Elevation of S2-bound alpha1-acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma.
    J Viral Hepat. 2024 Apr 12. doi: 10.1111/jvh.13943.
    PubMed     Abstract available
    
    
    March 2024
93. GUPTA N, Swindells S, Scarsi KK, Furl R, et al
    Preferences and feasibility of long-acting technologies for treatment of hepatitis C virus in low- and middle-income countries: A survey of providers and policymakers.
    J Viral Hepat. 2024 Mar 28. doi: 10.1111/jvh.13921.
    PubMed     Abstract available
    
    
    
94. NAVEED A, Khalid A, Janjua N, Cloherty GA, et al
    Performance of HCV core antigen and PCR testing in a predominantly genotype 3 population.
    J Viral Hepat. 2024 Mar 14. doi: 10.1111/jvh.13937.
    PubMed     Abstract available
    
    
    
95. DOBROWOLSKA K, Pawlowska M, Zarebska-Michaluk D, Rzymski P, et al
    Direct-acting antivirals in women of reproductive age infected with hepatitis C virus.
    J Viral Hepat. 2024 Mar 14. doi: 10.1111/jvh.13936.
    PubMed     Abstract available
    
    
    
96. HAVENS JR, Lofwall MR, Young AM, Staton M, et al
    Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community.
    J Viral Hepat. 2024 Mar 4. doi: 10.1111/jvh.13933.
    PubMed     Abstract available
    
    
    
97. SULKOWSKI MS, Martinez A, Tyson GL, Scholz K, et al
    Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs.
    J Viral Hepat. 2024 Mar 3. doi: 10.1111/jvh.13927.
    PubMed     Abstract available
    
    
    February 2024
98. WOLFSON-STOFKO B, Hirode G, Vanderhoff A, Karkada J, et al
    Real-world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada.
    J Viral Hepat. 2024 Feb 22. doi: 10.1111/jvh.13931.
    PubMed     Abstract available
    
    
    
99. FRYE K, Davis A, Darby R, McDaniel K, et al
    A contactless cure: Leveraging telehealth to improve hepatitis C treatment at a safety-net hospital.
    J Viral Hepat. 2024 Feb 18. doi: 10.1111/jvh.13913.
    PubMed     Abstract available
    
    
    
100. WALTER LA, Prados M, Lloyd A, Sontheimer S, et al
     Birth cohort-specific consideration in an Emergency Department Hepatitis C Testing Programme: A description of age-related characteristics and outcomes.
     J Viral Hepat. 2024 Feb 17. doi: 10.1111/jvh.13930.
     PubMed     Abstract available
     
     
     
101. TULLY DC, Power KA, Sarette J, Stopka TJ, et al
     Validation of dried blood spots for capturing hepatitis C virus diversity for genomic surveillance.
     J Viral Hepat. 2024 Feb 16. doi: 10.1111/jvh.13924.
     PubMed     Abstract available
     
     
     
102. EPSTEIN RL, Buzzee B, White LF, Feld JJ, et al
     Test characteristics for combining non-invasive liver fibrosis staging modalities in individuals with Hepatitis C virus.
     J Viral Hepat. 2024 Feb 7. doi: 10.1111/jvh.13925.
     PubMed     Abstract available
     
     
     
103. LV R, Lu Y, Xiang W, Meng M, et al
     Chronic viral hepatitis C micro-elimination program using telemedicine in Guigang city.
     J Viral Hepat. 2024 Feb 7. doi: 10.1111/jvh.13922.
     PubMed     Abstract available
     
     
     January 2024
104. POLLOCK TS, Robert CA, Seybold DJ, Hur M, et al
     Prevalence of hepatitis C among pregnant women in an Appalachian population.
     J Viral Hepat. 2024 Jan 18. doi: 10.1111/jvh.13911.
     PubMed     Abstract available
     
     
     
105. HIBBERT M, Simmons R, Sabin CA, Mandal S, et al
     Identifying missed opportunities for hepatitis C virus antenatal testing and diagnosis in England.
     J Viral Hepat. 2024 Jan 4. doi: 10.1111/jvh.13906.
     PubMed     Abstract available
     
     
     
106. QURESHI H, Duran AC, Mahmood H, Sarwar Z, et al
     Context-dependent accuracy of the cobas plasma separation card for HCV RNA viral load measurement.
     J Viral Hepat. 2024 Jan 2. doi: 10.1111/jvh.13910.
     PubMed     Abstract available
     
     
     December 2023
107. O'KEEFE D, Jacka D, Douglass C, Gunn J, et al
     Distribution of rapid HCV antibody self-test kits via needle/syringe dispensing machines: Implementation and evaluation of the Vend-C pilot study in Melbourne, Australia.
     J Viral Hepat. 2023 Dec 29. doi: 10.1111/jvh.13909.
     PubMed     Abstract available
     
     
     
108. ALQAHTANI SA, Stepanova M, Al Shabeeb R, Eberly KL, et al
     The impact of hepatitis B and C positive serologies on the outcomes of non-hepatic solid organ transplantation in the United States.
     J Viral Hepat. 2023 Dec 29. doi: 10.1111/jvh.13916.
     PubMed     Abstract available
     
     
     
109. TOYODA H, Koshiyama Y, Yasuda S, Kumada T, et al
     Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection.
     J Viral Hepat. 2023 Dec 26. doi: 10.1111/jvh.13907.
     PubMed     Abstract available
     
     
     
110. ZHOU S, Qi K, Bersoff-Matcha SJ, Mishra P, et al
     Sex-related difference analyses of efficacy and safety in clinical trials of direct-acting antivirals to treat chronic HCV genotype 1 and 3 infections.
     J Viral Hepat. 2023 Dec 19. doi: 10.1111/jvh.13901.
     PubMed     Abstract available
     
     
     
111. RAZAVI H, Blach S, Bregenzer A, Bruggmann P, et al
     Assessing the hepatitis C epidemiology in Switzerland: It is not that trivial.
     J Viral Hepat. 2023 Dec 8. doi: 10.1111/jvh.13904.
     PubMed    
     
     
     November 2023
112. O'SULLIVAN M, Jones AM, Mourad A, Haddadin Y, et al
     Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated-Test-stage Treat study final outcomes.
     J Viral Hepat. 2023 Nov 28. doi: 10.1111/jvh.13897.
     PubMed     Abstract available
     
     
     
113. HAJARIZADEH B, Carson JM, Byrne M, Grebely J, et al
     Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
     J Viral Hepat. 2023 Nov 7. doi: 10.1111/jvh.13895.
     PubMed     Abstract available
     
     
     
114. TRELOAR C, Rance J, Bryant J, Lafferty L, et al
     "There's too much power in this number. It's freaking the whole response out": the views of key informants on evidence and targets to achieve hepatitis C elimination goals in Australia.
     J Viral Hepat. 2023 Nov 2. doi: 10.1111/jvh.13896.
     PubMed     Abstract available
     
     
     October 2023
115. BERTISCH B, Schaetti C, Schmid P, Peter L, et al
     Chronic hepatitis C virus infections in Switzerland in 2020: Lower than expected and suggesting achievement of WHO elimination targets.
     J Viral Hepat. 2023 Oct 7. doi: 10.1111/jvh.13892.
     PubMed    
     
     
     September 2023
116. EVANS KN, Vettese T, Wortley PM, Gandhi AP, et al
     HIV and HCV testing at clinical encounters among people who inject drugs, 2013-2018-Opportunities for increased testing and prevention.
     J Viral Hepat. 2023 Sep 19. doi: 10.1111/jvh.13877.
     PubMed     Abstract available
     
     
     
117. CAROLINE A, Kate M, Roberts M, Ryan J, et al
     What is the impact of a Hepatitis C 'test, trace and treat' pilot using peer workers?
     J Viral Hepat. 2023 Sep 18. doi: 10.1111/jvh.13888.
     PubMed     Abstract available
     
     
     
118. JOHNSON A, Shearer J, Thompson C, Jelley R, et al
     Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
     J Viral Hepat. 2023 Sep 12. doi: 10.1111/jvh.13887.
     PubMed     Abstract available
     
     
     August 2023
119. BLACH S, Bregenzer A, Bruggmann P, Cerny A, et al
     Assessing the hepatitis C epidemiology in Switzerland: it's not that trivial.
     J Viral Hepat. 2023 Aug 8. doi: 10.1111/jvh.13879.
     PubMed    
     
     
     July 2023
120. PERAZZO H, Castro R, Villela-Nogueira C, Torres M, et al
     Acceptability and usability of oral fluid HCV self-testing for hepatitis C diagnosis: A systematic review and meta-analysis.
     J Viral Hepat. 2023 Jul 23. doi: 10.1111/jvh.13876.
     PubMed     Abstract available
     
     
     
121. TORRES C, Bauer G, Aubriet S, Scholtes C, et al
     Profile of patients with a positive HCV viral load in a large French psychiatric hospital (2019-2021): A case-control study.
     J Viral Hepat. 2023 Jul 23. doi: 10.1111/jvh.13875.
     PubMed     Abstract available
     
     
     
122. ROSSOTTI R
     Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply.
     J Viral Hepat. 2023 Jul 11. doi: 10.1111/jvh.13871.
     PubMed    
     
     
     
123. LU M, Salgia R, Li J, Trudeau S, et al
     Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C.
     J Viral Hepat. 2023 Jul 6. doi: 10.1111/jvh.13859.
     PubMed     Abstract available
     
     
     June 2023
124. COYLE CR, Desjardins MR, Curriero FC, Rudolph J, et al
     Geographic variation in HCV treatment penetration among people who inject drugs in Baltimore, MD.
     J Viral Hepat. 2023 Jun 29. doi: 10.1111/jvh.13864.
     PubMed     Abstract available
     
     
     
125. GORDON SC, Kaushik A, Chastek B, Anderson A, et al
     Characteristics associated with receipt of treatment among patients diagnosed with chronic hepatitis C virus.
     J Viral Hepat. 2023 Jun 28. doi: 10.1111/jvh.13860.
     PubMed     Abstract available
     
     
     
126. BARRE T, Zucman D, Marcellin F, Ramier C, et al
     Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH).
     J Viral Hepat. 2023 Jun 26. doi: 10.1111/jvh.13865.
     PubMed    
     
     
     
127. TRICKEY A, Ingle SM, Boyd A, Gill MJ, et al
     Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality: A collaboration of cohort studies.
     J Viral Hepat. 2023 Jun 20. doi: 10.1111/jvh.13863.
     PubMed     Abstract available
     
     
     
128. HOVAGUIMIAN F, Beeler PE, Mullhaupt B, Gunthard HF, et al
     Mortality and morbidity related to hepatitis C virus infection in hospitalized adults-A propensity score matched analysis.
     J Viral Hepat. 2023 Jun 12. doi: 10.1111/jvh.13861.
     PubMed     Abstract available
     
     
     
129. BERTISCH B, Schaetti C, Schmid P, Peter L, et al
     Chronic hepatitis C virus infections in Switzerland in 2020: Lower than expected and suggesting achievement of WHO elimination targets.
     J Viral Hepat. 2023 Jun 6. doi: 10.1111/jvh.13842.
     PubMed     Abstract available
     
     
     
130. DE A, Charak S, Bhagat N, Rathi S, et al
     Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy.
     J Viral Hepat. 2023 Jun 1. doi: 10.1111/jvh.13844.
     PubMed     Abstract available
     
     
     May 2023
131. JACOBSON IM, Bourgeois S, Mathurin P, Thuluvath P, et al
     The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis.
     J Viral Hepat. 2023;30:448-454.
     PubMed     Abstract available
     
     
     April 2023
132. PASSOS-CASTILHO AM, Murphy DG, Blouin K, Benedetti A, et al
     A population-based study of reported hepatitis C diagnoses from 1998 to 2018 in immigrants and nonimmigrants in Quebec, Canada.
     J Viral Hepat. 2023 Apr 18. doi: 10.1111/jvh.13837.
     PubMed     Abstract available
     
     
     March 2023
133. HIBBERT M, Simmons R, Harris H, Desai M, et al
     Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England.
     J Viral Hepat. 2023 Mar 17. doi: 10.1111/jvh.13835.
     PubMed     Abstract available
     
     
     
134. MOREAU C, Roux M, Riou J, Canivet CM, et al
     Dynamic Personalized Prediction of the Individual Liver-Related Risk after Sustained Viral Response in HCV patients.
     J Viral Hepat. 2023 Mar 9. doi: 10.1111/jvh.13830.
     PubMed     Abstract available
     
     
     
135. QIU L, Xu S, Qiu Y, Liu Y, et al
     Comparison of acknowledged hepatocellular carcinoma risk scores in high risk hepatitis C patients with sustained virologic response.
     J Viral Hepat. 2023 Mar 8. doi: 10.1111/jvh.13829.
     PubMed     Abstract available
     
     
     
136. MOONEYHAN E, De la Torre Rosas A, Serrano DB, Gamkrelidze I, et al
     Cost-effectiveness and economic investment to eliminate chronic hepatitis C in Mexico.
     J Viral Hepat. 2023 Mar 8. doi: 10.1111/jvh.13828.
     PubMed     Abstract available
     
     
     
137. SELIM R, Zhou Y, Gordon SC, Zhang T, et al
     Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct-acting antivirals.
     J Viral Hepat. 2023 Mar 5. doi: 10.1111/jvh.13826.
     PubMed     Abstract available
     
     
     February 2023
138. SHAH SHBU, Alavi M, Hajarizadeh B, Matthews G, et al
     Liver-related mortality among people with hepatitis B and C: evaluation of definitions based on linked healthcare administrative datasets.
     J Viral Hepat. 2023 Feb 27. doi: 10.1111/jvh.13824.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.